[
  {
    "ts": null,
    "headline": "The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot",
    "summary": "The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.",
    "url": "https://finnhub.io/api/news?id=fcf1649587c0acd862a995caa6aff174aeabe308fa4e5b186969bac84c38232c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761933600,
      "headline": "The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot",
      "id": 137279127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.",
      "url": "https://finnhub.io/api/news?id=fcf1649587c0acd862a995caa6aff174aeabe308fa4e5b186969bac84c38232c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb's Lack of Update on Phase 3 Alzheimer's Trial 'Surprising,' Morgan Stanley Says",
    "summary": "Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th",
    "url": "https://finnhub.io/api/news?id=b6f2aab23229a1fd12161b5122cbd1fce08175334e2b7d119a664a5bd6465a78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761921473,
      "headline": "Bristol-Myers Squibb's Lack of Update on Phase 3 Alzheimer's Trial 'Surprising,' Morgan Stanley Says",
      "id": 137279250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th",
      "url": "https://finnhub.io/api/news?id=b6f2aab23229a1fd12161b5122cbd1fce08175334e2b7d119a664a5bd6465a78"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]",
    "url": "https://finnhub.io/api/news?id=216856d06079e243442c941a79054a5c2368c061d9237b355f2fb64fa898f722",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761903776,
      "headline": "Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data",
      "id": 137277422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]",
      "url": "https://finnhub.io/api/news?id=216856d06079e243442c941a79054a5c2368c061d9237b355f2fb64fa898f722"
    }
  },
  {
    "ts": null,
    "headline": "Atrial Fibrillation Eight-Market Drug Forecast and Market Analysis 2022-2024 & 2025-2032: Market to Remain Dominated by Bayer and Bristol Myers Squibb; Growth Driven by Milvexian Launch",
    "summary": "The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The \"Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update\" report has been added to ResearchAndMarkets.com's offering.The table below pres",
    "url": "https://finnhub.io/api/news?id=5766ca101292242e3da4696a3d8a6c663c1066c3041d4a863394952f600719c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761902760,
      "headline": "Atrial Fibrillation Eight-Market Drug Forecast and Market Analysis 2022-2024 & 2025-2032: Market to Remain Dominated by Bayer and Bristol Myers Squibb; Growth Driven by Milvexian Launch",
      "id": 137277423,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The \"Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update\" report has been added to ResearchAndMarkets.com's offering.The table below pres",
      "url": "https://finnhub.io/api/news?id=5766ca101292242e3da4696a3d8a6c663c1066c3041d4a863394952f600719c5"
    }
  },
  {
    "ts": null,
    "headline": "Strong Trial Results in Autoimmune Diseases Might Change the Case for Investing in Bristol-Myers Squibb (BMY)",
    "summary": "In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...",
    "url": "https://finnhub.io/api/news?id=f27c0cf87d03c2e5fa71a640345b1167e59c7f10ad1adb06762d21851cc6959d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761880936,
      "headline": "Strong Trial Results in Autoimmune Diseases Might Change the Case for Investing in Bristol-Myers Squibb (BMY)",
      "id": 137275175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...",
      "url": "https://finnhub.io/api/news?id=f27c0cf87d03c2e5fa71a640345b1167e59c7f10ad1adb06762d21851cc6959d"
    }
  }
]